Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 10, 2026

ZenaTech anuncia su 21ª adquisición, ampliando su red nacional de Drone como Servicio y su presencia en el noroeste del Pacífico para atender a empresas y gobiernos

View original at globenewswire.com
ZenaTech anuncia su 21ª adquisición, ampliando su red nacional de Drone como Servicio y su presencia en el noroeste del Pacífico para atender a empresas y gobiernos VANCOUVER, British Columbia, April 10, 2026 (GLOBE NEWSWIRE) -- ZenaTech, Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • ZenaTech is bringing field efficiency as well as high-value data and insights that help businesses and governments make faster and smarter decisions at scale

    60% confidence

  • DaaS goes beyond flying drones by providing an AI-driven autonomy platform that converts aerial operations into continuous, actionable intelligence while automating labor-intensive manual tasks

    60% confidence

  • Strengthening operations in the Pacific Northwest positions ZenaTech at the intersection of forestry and environmental monitoring, critical energy infrastructure, and port and logistics surveillance, which is precisely where Drone as a Service offers the greatest value for mission-critical operations

    60% confidence

Data points we hold from this source

ZenaTech, Inc. · acquisition count21 acquisitions
ZenaTech, Inc. · daas location count24 locations
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com
ZenaTech anuncia su 21ª adquisición, ampliando su red nacional de Drone como Servicio y su presencia en el noroeste del Pacífico para atender a empresas y gobiernos — Source | Via News | ViaNews EU